Expertise in
27
conditions

Dr. Neil E. Faulkner

Oncology
University Of Tennessee Medical Center
1924 Alcoa Hwy, 
Knoxville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
27
conditions
University Of Tennessee Medical Center
1924 Alcoa Hwy, 
Knoxville, TN 

Overview

Neil Faulkner is an Oncologist practicing medicine in Knoxville, Tennessee.

Dr. Faulkner is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Anal Cancer, Pleuropulmonary Blastoma, and Laryngeal Cancer.

He is actively involved in clinical research, participating in 7 clinical trials. Dr. Faulkner is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MI

Hospital Affiliations

University Health System, Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

University of Tennessee Medical Center
1924 Alcoa Hwy, Knoxville, TN 37920

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Enrollment Status: Terminated
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Trilaciclib, Docetaxel
Study Phase: Phase 2
A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer
A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 2
View 6 Less Clinical Trials
Similar Doctors
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Referral may be required

TriStar Medical Group Children's Specialists - West Clinch Ave

2018 Clinch Ave, 
Knoxville, TN 
 (1.1 miles away)
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Haydar Frangoul is a Hematologist and an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Frangoul is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Frangoul is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Office

1928 Alcoa Hwy Ste 127, 
Knoxville, TN 
 (4.6 miles away)
865-305-8787
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Larry Kilgore is an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Kilgore is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Desmoplastic Small Round Cell Tumor, Ovarian Cancer, Ovarian Carcinosarcoma, and Ureteroscopy. Dr. Kilgore is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

University Of Tennessee Medical Center

1924 Alcoa Hwy, 
Knoxville, TN 
 (0.1 miles away)
865-305-6740
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kristopher Kimball is an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Kimball is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Bladder Reconstruction. Dr. Kimball is currently accepting new patients.

Frequently Asked Questions about Dr. Neil E. Faulkner

How do I make an appointment with Dr. Neil E. Faulkner?

You can book an appointment with Dr. Neil E. Faulkner by calling their office at 865-305-8780. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Neil E. Faulkner a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Neil E. Faulkner is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Neil E. Faulkner specialize in?

While Dr. Neil E. Faulkner is a Oncology, they have specific expertise in Lung Cancer, Anal Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Neil E. Faulkner accept my insurance?

Dr. Neil E. Faulkner accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 865-305-8780 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Faulkner's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile